Fenoplast Capital Restructuring: NCLT Approves 1-for-20 Share Swap, Promoter Stake Eliminated

Fenoplast Limited has set March 23, 2026, as the record date for its equity share capital reduction. This follows the approval of a resolution plan by the National Company Law Tribunal (NCLT) Hyderabad Bench.

Plan Details

Fenoplast Limited announced March 23, 2026, as the record date for its equity share capital reduction. This follows the approval of a resolution plan by the National Company Law Tribunal (NCLT) Hyderabad Bench.

The plan will extinguish all promoter holdings. It also involves reducing the equity held by public shareholders. Public shareholders will receive one new Rs.10 share for every 20 existing Rs.10 shares they hold.

Significance

This capital restructuring represents a major overhaul for Fenoplast Limited, stemming from a court-approved resolution after insolvency proceedings. The complete exit of promoters and substantial reduction of public shareholding signal a new chapter for the company.

The NCLT's approval formalizes a process to address the company's financial distress and prepare for its potential revival under new ownership.

Background

Fenoplast Limited entered Corporate Insolvency Resolution Process (CIRP) on February 7, 2023, after a petition by Canara Bank. This followed an earlier NCLT order in October 2022 to start CIRP, which was later recalled due to misrepresentation by the bank regarding a One Time Settlement.

The NCLT approved the resolution plan on January 22, 2025. The plan, submitted by Resolution Applicant Mr. Krishna Kumar Haridas (a promoter-linked entity), includes significant capital restructuring.

Key Changes

• Promoter Exit: The entire shareholding of the promoter group will be extinguished, marking their exit.
• Public Shareholder Dilution: Public shareholders will see significant dilution, with their capital reduced by up to 95% via the 1-for-20 share swap.
• New Capital Structure: The company will operate with a much smaller equity capital base, as per the NCLT's plan.
• Potential for Revival: The restructuring is designed to stabilize the company's finances and pave the way for its operational revival.

Potential Risks

• Execution of Plan: Successfully implementing the NCLT-approved resolution plan is crucial.
• Future Viability: The long-term viability of Fenoplast after restructuring will be a key concern for stakeholders.
• Regulatory Compliance: Adherence to NCLT and other regulatory directives will be closely monitored.

Market Context

Companies emerging from Corporate Insolvency Resolution Process (CIRP) through NCLT-approved plans, often under the Insolvency and Bankruptcy Code (IBC), offer a comparative context. However, direct comparisons for such extensive capital reduction and promoter exits are rare.

Key Dates

• CIRP initiated: February 7, 2023, as per NCLT order.
• Resolution plan approved: January 22, 2025.
• Record date for capital reduction: March 23, 2026.

Next Steps

• Shareholder actions: Monitor for any further procedural steps or approvals needed post-NCLT order.
• Delisting potential: Assess the implications of the drastic capital reduction on the company's stock listing status.
• Operational revival: Track the company's strategy and execution for resuming and growing operations.
• New management/ownership: Seek clarity on future leadership and ownership after the promoter exit.